#METABOLOMICS WORKBENCH efahy_20230425_000035 DATATRACK_ID:3930 STUDY_ID:ST002614 ANALYSIS_ID:AN004286 PROJECT_ID:PR001020
VERSION             	1
CREATED_ON             	April 25, 2023, 7:56 am
#PROJECT
PR:PROJECT_TITLE                 	Molecular Transducer of Physical Activity Consortium
PR:PROJECT_SUMMARY               	MoTrPAC is a national research consortium designed to discover and perform
PR:PROJECT_SUMMARY               	preliminary characterization of the range of molecular transducers (the
PR:PROJECT_SUMMARY               	"molecular map") that underlie the effects of physical activity in humans. The
PR:PROJECT_SUMMARY               	program's goal is to study the molecular changes that occur during and after
PR:PROJECT_SUMMARY               	exercise and ultimately to advance the understanding of how physical activity
PR:PROJECT_SUMMARY               	improves and preserves health. Preclinical and clinical studies will examine the
PR:PROJECT_SUMMARY               	systemic effects of endurance and resistance exercise across a range of ages and
PR:PROJECT_SUMMARY               	fitness levels by molecular probing of multiple tissues before and after acute
PR:PROJECT_SUMMARY               	and chronic exercise. This program is the largest targeted NIH investment of
PR:PROJECT_SUMMARY               	funds into the mechanisms of how physical activity improves health and prevents
PR:PROJECT_SUMMARY               	disease. The MoTrPAC program is supported by the NIH Common Fund and is managed
PR:PROJECT_SUMMARY               	by a trans-agency working group representing multiple NIH institutes and
PR:PROJECT_SUMMARY               	centers, led by the NIH Office of Strategic Coordination, National Institute of
PR:PROJECT_SUMMARY               	Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes
PR:PROJECT_SUMMARY               	and Digestive and Kidney Diseases, National Institute on Aging, and National
PR:PROJECT_SUMMARY               	Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee:
PR:PROJECT_SUMMARY               	Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion
PR:PROJECT_SUMMARY               	Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac
PR:PROJECT_SUMMARY               	Bioinformatics / Data Coordination Center.
PR:INSTITUTE                     	MoTrPAC
PR:LAST_NAME                     	Ashley
PR:FIRST_NAME                    	Euan A.
PR:ADDRESS                       	300 Pasteur Dr Rm A265. MC 5319. Stanford CA 94305. USA
PR:EMAIL                         	euan@stanford.edu
PR:PHONE                         	(650) 498-4900
#STUDY
ST:STUDY_TITLE                   	MoTrPAC: Endurance exercise training study in young adult rats, Rat Liver Powder
ST:STUDY_TITLE                   	- Targeted Keto Acids
ST:STUDY_SUMMARY                 	The goal of the endurance exercise training study in young adult rats (internal
ST:STUDY_SUMMARY                 	code: PASS1B-06) was to perform exercise training studies in adult (6 month)
ST:STUDY_SUMMARY                 	F344 rats, and from these rats collect as many tissues as feasible in order to
ST:STUDY_SUMMARY                 	provide high quality samples for detailed analysis by chemical analysis sites.
ST:STUDY_SUMMARY                 	Tissues were collected from 10-12 rats sedentary control rats concurrent with
ST:STUDY_SUMMARY                 	the collection of the 8-week training groups. The 8-week training group and
ST:STUDY_SUMMARY                 	controls were from the same cohort and same age at euthanasia (either 8). For
ST:STUDY_SUMMARY                 	the older age group, an additional set of controls (n=5-6) were collected with
ST:STUDY_SUMMARY                 	the 1-2 week training group. Rats were either sedentary or underwent an exercise
ST:STUDY_SUMMARY                 	training program. Rats were exercised on the rodent treadmill 5 days per week
ST:STUDY_SUMMARY                 	using a progressive training protocol designed to exercise the rats at
ST:STUDY_SUMMARY                 	approximately 70% of VO2max as outlined in the Table on the next page. Training
ST:STUDY_SUMMARY                 	was performed no earlier than 10:00 am and no later than 5:00 pm over 5
ST:STUDY_SUMMARY                 	consecutive days per week. Training was initiated with the treadmill set at 70%
ST:STUDY_SUMMARY                 	of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of
ST:STUDY_SUMMARY                 	exercise was increased by one minute each day until day 31 of training (start of
ST:STUDY_SUMMARY                 	week 7), when a duration of 50 min was reached. Speed and grade of each training
ST:STUDY_SUMMARY                 	session increased in larger increments due to treadmill parameters. The highest
ST:STUDY_SUMMARY                 	intensity and duration of training began on day 31. This intensity was
ST:STUDY_SUMMARY                 	maintained for the final 10 days of the protocol to ensure steady state had been
ST:STUDY_SUMMARY                 	achieved. If any rats were unable to perform at least 4 days of training per
ST:STUDY_SUMMARY                 	week they were removed from the study and euthanized. It is important to note
ST:STUDY_SUMMARY                 	that the starting treadmill speed varied depending on the sex and age of the
ST:STUDY_SUMMARY                 	rat. The initial and maximum speeds were based on VO2max measurements obtained
ST:STUDY_SUMMARY                 	during the pre-training testing of the compliant rats. Rats assigned to the
ST:STUDY_SUMMARY                 	control group followed a schedule similar to the training group. They were
ST:STUDY_SUMMARY                 	placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The
ST:STUDY_SUMMARY                 	treadmill was set at 0 m/min at an incline that corresponded to the incline
ST:STUDY_SUMMARY                 	being used by the training group.
ST:INSTITUTE                     	Duke University
ST:DEPARTMENT                    	Duke Molecular Physiology Institute
ST:LABORATORY                    	Metabolomics Core Laboratory
ST:LAST_NAME                     	Newgard
ST:FIRST_NAME                    	Christopher
ST:ADDRESS                       	300 N Duke St, Durham, NC 27701
ST:EMAIL                         	chris.newgard@duke.edu
ST:PHONE                         	(919) 668-6059
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Rattus norvegicus
SU:TAXONOMY_ID                   	10116
#SUBJECT_SAMPLE_FACTORS:          	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	80010816802_1	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a023.zip
SUBJECT_SAMPLE_FACTORS           	-	80011826802_1	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a024.zip
SUBJECT_SAMPLE_FACTORS           	07AF7369-F082-4CA7-99D5-D973F4A162C9	90252016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a025.zip
SUBJECT_SAMPLE_FACTORS           	4E974304-21EB-42E8-A729-A7FB6B406E64	90439016811	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a026.zip
SUBJECT_SAMPLE_FACTORS           	B73AB139-7210-4498-9CCF-E1DBE6EBA71C	90559016811	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a027.zip
SUBJECT_SAMPLE_FACTORS           	E4271AF1-899A-4A65-9D8D-BF18CEE3F1CF	90292016811	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a028.zip
SUBJECT_SAMPLE_FACTORS           	DC8B35E8-4AA8-4829-8569-F223D069620C	90578016811	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a029.zip
SUBJECT_SAMPLE_FACTORS           	B137E81D-A9DE-4E3A-8E2B-AD6C22920B7E	90576016811	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a030.zip
SUBJECT_SAMPLE_FACTORS           	CFE06932-9314-4BCC-B2D9-73883D5FCDFB	90223016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a031.zip
SUBJECT_SAMPLE_FACTORS           	9F3E1040-D409-421E-B635-2572DC20ED89	90283016811	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a032.zip
SUBJECT_SAMPLE_FACTORS           	1628FB23-6F66-47D4-8D82-63C87726F0FD	90245016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a033.zip
SUBJECT_SAMPLE_FACTORS           	89D6F615-D17C-4EB9-88EB-A602940FF179	90416016811	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a034.zip
SUBJECT_SAMPLE_FACTORS           	3719CB62-B551-49BE-94A0-E51DFE13D30D	90225016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a035.zip
SUBJECT_SAMPLE_FACTORS           	2B969165-1A52-43AA-8FD9-39AFA62F094F	90267016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a036.zip
SUBJECT_SAMPLE_FACTORS           	FDA87A8D-3634-4C42-9A1A-0EA03B58BB01	90449016811	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a037.zip
SUBJECT_SAMPLE_FACTORS           	1F9BD644-303F-43E7-94BE-FF6654306F5E	90585016811	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a038.zip
SUBJECT_SAMPLE_FACTORS           	EA5C8932-9325-4DA5-96BB-50CD49CEDD10	90560016811	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a039.zip
SUBJECT_SAMPLE_FACTORS           	0DBFEB04-1B58-43CF-BAFD-9AA9915B67F6	90426016811	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a040.zip
SUBJECT_SAMPLE_FACTORS           	A77AC89A-1D9E-4516-9DA4-2BE99C8126EF	90266016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a041.zip
SUBJECT_SAMPLE_FACTORS           	-	80010816802_2	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a042.zip
SUBJECT_SAMPLE_FACTORS           	-	80011826802_2	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a043.zip
SUBJECT_SAMPLE_FACTORS           	6A013AA1-4D1E-4B75-B691-6BA22D928E51	90571016811	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a044.zip
SUBJECT_SAMPLE_FACTORS           	69FD4884-786D-4F2A-97B1-6174FBD25D60	90248016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a045.zip
SUBJECT_SAMPLE_FACTORS           	FE012DC0-AF32-4C70-A4D4-F042B8BC4EC6	90420016811	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a046.zip
SUBJECT_SAMPLE_FACTORS           	0645F621-878C-4C9B-84A6-58862BAA17D9	90564016811	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a047.zip
SUBJECT_SAMPLE_FACTORS           	F65955CE-E49F-48C7-B861-02A2FDF6F9B8	90227016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a048.zip
SUBJECT_SAMPLE_FACTORS           	3D5BC47C-BB3D-45A2-8DB8-D7ADCD51997C	90412016811	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a049.zip
SUBJECT_SAMPLE_FACTORS           	2E37478F-525F-4E5E-A882-EE75FD0CFB29	90406016811	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a050.zip
SUBJECT_SAMPLE_FACTORS           	10E282EB-1DBA-406E-BD5D-81027083A01D	90430016811	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a051.zip
SUBJECT_SAMPLE_FACTORS           	0BD282C7-7832-4581-9089-08A32D557034	90218016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a052.zip
SUBJECT_SAMPLE_FACTORS           	569A9229-04E8-414A-A195-FE9E8F1B66AB	90289016811	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a053.zip
SUBJECT_SAMPLE_FACTORS           	04C84D7E-FC8C-422F-AE4B-CAFADB63407B	90259016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a054.zip
SUBJECT_SAMPLE_FACTORS           	F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF	90237016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a055.zip
SUBJECT_SAMPLE_FACTORS           	0A4A7935-3AF4-463F-84E3-DCF07671509D	90258016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a056.zip
SUBJECT_SAMPLE_FACTORS           	90CFE5A4-76FE-4458-A2B1-A66F0B60118E	90232016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a057.zip
SUBJECT_SAMPLE_FACTORS           	8904857C-2073-4BBA-AC7C-1EC239E5BFF7	90581016811	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a058.zip
SUBJECT_SAMPLE_FACTORS           	BC49E4EF-E2FE-4269-BAF0-461F768BD95D	90217016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a059.zip
SUBJECT_SAMPLE_FACTORS           	1CA4210C-3CE6-4A5A-996B-673EBDEB3B81	90281016811	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a060.zip
SUBJECT_SAMPLE_FACTORS           	-	80010816802_3	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a061.zip
SUBJECT_SAMPLE_FACTORS           	-	80011826802_3	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a062.zip
SUBJECT_SAMPLE_FACTORS           	6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0	90441016811	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a063.zip
SUBJECT_SAMPLE_FACTORS           	955498F4-70A0-4D50-A2BA-619A8FED8FEF	90222016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a064.zip
SUBJECT_SAMPLE_FACTORS           	F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17	90265016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a065.zip
SUBJECT_SAMPLE_FACTORS           	53F914B0-FD4F-4340-84A6-48341EAB3798	90422016811	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a066.zip
SUBJECT_SAMPLE_FACTORS           	22D700B9-EDD0-4BC8-8155-EB9C39417F81	90280016811	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a067.zip
SUBJECT_SAMPLE_FACTORS           	A9CE3E3D-31A0-4443-8A7F-8FD831D79248	90410016811	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a068.zip
SUBJECT_SAMPLE_FACTORS           	0559B193-BED3-4170-B045-10A2B6441CB6	90229016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a069.zip
SUBJECT_SAMPLE_FACTORS           	CDCFA3F1-07ED-4737-A36D-15EFEC325AA5	90450016811	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a070.zip
SUBJECT_SAMPLE_FACTORS           	AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504	90444016811	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a071.zip
SUBJECT_SAMPLE_FACTORS           	0409BED3-F9FE-4C06-9920-74F5E5CA04A3	90587016811	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a072.zip
SUBJECT_SAMPLE_FACTORS           	0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E	90251016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a073.zip
SUBJECT_SAMPLE_FACTORS           	D350D633-8D95-4783-99F2-BB8294D2EC32	90423016811	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a074.zip
SUBJECT_SAMPLE_FACTORS           	6D680EA2-C62B-4A35-8B6E-2ED6A79CB017	90421016811	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a075.zip
SUBJECT_SAMPLE_FACTORS           	68083256-8DAA-4185-B446-0CAF600474B5	90567016811	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a076.zip
SUBJECT_SAMPLE_FACTORS           	2479BEE5-2A38-4D09-B15B-B1715F561A9F	90254016811	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=Motorpac_PASS1B_Liver_081020_a077.zip
SUBJECT_SAMPLE_FACTORS           	FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC	90239016811	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=Motorpac_PASS1B_Liver_081020_a078.zip
SUBJECT_SAMPLE_FACTORS           	-	80010816802_4	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a079.zip
SUBJECT_SAMPLE_FACTORS           	-	80011826802_4	Group:QC-ExternalStandard | Timepoint:0 hour | Sex:-	raw_file=Motorpac_PASS1B_Liver_081020_a080.zip
#COLLECTION
CO:SAMPLE_TYPE                   	Liver
#TREATMENT
TR:TREATMENT_SUMMARY             	-
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	10 µl of plasma or 300 µl of tissue homogenate prepared at 100 mg/ml in 3M
SP:SAMPLEPREP_SUMMARY            	perchloric acid containing isotopically labeled internal standards KIC-d3,
SP:SAMPLEPREP_SUMMARY            	KIV-5C13, (Cambridge Isotope Laboratories), and KMV-d8 (Toronto Research
SP:SAMPLEPREP_SUMMARY            	Chemicals) are precipitated with 150 µl of 3M PCA. 200 µl of 25 M
SP:SAMPLEPREP_SUMMARY            	o-phenylenediamine (OPD) in 3M HCl is added to the supernatants and the samples
SP:SAMPLEPREP_SUMMARY            	are incubated at 80oC for 20 minutes. Keto acids are extracted with ethyl
SP:SAMPLEPREP_SUMMARY            	acetate. The extracts are dried under nitrogen and reconstituted in 200 mM
SP:SAMPLEPREP_SUMMARY            	ammonium acetate.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	The analytical column is used at 30°C. 10 µl of the sample are injected onto the
CH:CHROMATOGRAPHY_SUMMARY        	column and eluted at a flow rate of 0.4 ml/min. The gradient begins with 45%
CH:CHROMATOGRAPHY_SUMMARY        	eluent A (5 mM ammonium acetate in water) and is then programmed as follows: 0
CH:CHROMATOGRAPHY_SUMMARY        	to 2 min – gradient to 55% eluent B (methanol); 2 to 2.5 min - gradient to 95%
CH:CHROMATOGRAPHY_SUMMARY        	eluent B; 2.5 to 3.2 min - hold at 95% eluent B, return to 45% A, and
CH:CHROMATOGRAPHY_SUMMARY        	re-equilibrate the column at initial conditions for 1 minute.
CH:CHROMATOGRAPHY_TYPE           	RP
CH:INSTRUMENT_NAME               	Waters Acquity UPLC
CH:COLUMN_NAME                   	Waters Acquity UPLC BEH C18 (50 x 2.1 mm,1.7 um)
CH:SOLVENT_A                     	100% water; 5 mM ammonium acetate
CH:SOLVENT_B                     	100% methanol
CH:FLOW_GRADIENT                 	45% A and 55% B for 2 minutes, followed by a linear gradient to 95% B from 2 to
CH:FLOW_GRADIENT                 	2.5 minutes, held at 95% B for 0.7 minutes, returned to 45% A, and finally the
CH:FLOW_GRADIENT                 	column was re-equilibrated at initial conditions for 1 minute. The total run
CH:FLOW_GRADIENT                 	time was 4.7 minutes.
CH:FLOW_RATE                     	0.4 ml/min
CH:COLUMN_TEMPERATURE            	30C
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:ANALYSIS_DETAILS:             	Ion ratios of keto acids to respective internal standards are computed from
AN:ANALYSIS_DETAILS:             	extracted ion chromatograms using a software package TargetLynx (Waters,
AN:ANALYSIS_DETAILS:             	Milford, MA). The ratios are converted to concentrations using calibrators
AN:ANALYSIS_DETAILS:             	constructed from authentic keto acids (Sigma, MO, USA) and Dialyzed Fetal Bovine
AN:ANALYSIS_DETAILS:             	Serum (Sigma, MO, USA). The values are expressed in µM units for plasma samples
AN:ANALYSIS_DETAILS:             	or pmol/mg for tissue samples.
#MS
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:INSTRUMENT_NAME               	Waters Xevo TQ-S
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Mass transitions of m/z 203 -> 161 (ketoleucine or KIC), 206 -> 161 (KIC-d3),
MS:MS_COMMENTS                   	189 -> 174 (ketoisovalerate or KIV), 194 -> 178 (KIV-5C13), 203 -> 174
MS:MS_COMMENTS                   	(3-methyl-2-oxovalerate or KMV), and 211 -> 177 (KMV-d8) are monitored in a
MS:MS_COMMENTS                   	positive ion electrospray ionization mode.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	pmol/mg of tissue
MS_METABOLITE_DATA_START
Samples	90217016811	90218016811	90222016811	90223016811	90225016811	90227016811	90229016811	90232016811	90237016811	90239016811	90245016811	90248016811	90251016811	90252016811	90254016811	90258016811	90259016811	90265016811	90266016811	90267016811	90280016811	90281016811	90283016811	90289016811	90292016811	90406016811	90410016811	90412016811	90416016811	90420016811	90421016811	90422016811	90423016811	90426016811	90430016811	90439016811	90441016811	90444016811	90449016811	90450016811	90559016811	90560016811	90564016811	90567016811	90571016811	90576016811	90578016811	90581016811	90585016811	90587016811	80010816802_1	80010816802_2	80010816802_3	80010816802_4	80011826802_1	80011826802_2	80011826802_3	80011826802_4
ketoisovalerate	0.257058922	0.241453044	0.220836858	0.264204771	0.260618157	0.197373284	0.245505097	0.316224363	0.29489633	0.327696052	0.382727305	0.347353982	0.257113679	0.235429723	0.179987789	0.378155057	0.396307157	0.22792795	0.574706979	0.493392143	0.270310228	0.342316296	0.228201737	0.368983181	0.377388452	0.204546512	0.177441567	0.438497784	0.277319184	0.308695212	0.123751872	0.151842452	0.179768759	0.269351973	0.208023611	0.211062651	0.224943668	0.245450339	0.298921004	0.207257007	0.211281681	0.276525201	0.219276271	0.312966294	0.139987461	0.254156776	0.340399784	0.265108269	0.220480935	0.159371603	0.206517781	0.243013632	0.246244322	0.216976457	0.235238072	0.215470627	0.214731401	0.193211717
ketoleucine	0.24175987	0.275469059	0.259279528	0.368007814	0.192763735	0.208278703	0.238947604	0.383532282	0.148328032	0.232163963	0.187110701	0.324892735	0.323315586	0.144470667	0.207423622	0.573645267	0.242804969	0.131530443	0.282309706	0.261920778	0.236382362	0.118799238	0.196763614	0.224373226	0.343286475	0.151786359	0.192146177	0.252077847	0.145173733	0.241246822	0.153249497	0.149430136	0.118115174	0.139226171	0.198739801	0.195604504	0.133183599	0.198853812	0.141468383	0.170389119	0.152869461	0.210026869	0.105307962	0.156099767	0.117089077	0.14460368	0.119882341	0.128889193	0.125715893	0.126304948	0.192545215	0.186502643	0.186559649	0.180270054	0.142266458	0.136907951	0.131967484	0.134342709
3-methyl-2-oxovalerate	0.408785212	0.37969264	0.490717767	0.541164394	0.273999378	0.253935076	0.456918262	0.577463628	0.285341226	0.489813611	0.285607155	0.446201345	0.446680016	0.28874511	0.282522385	0.588499658	0.307014395	0.228645281	0.468512742	0.418225672	0.418651158	0.252392691	0.325602793	0.411444497	0.259546167	0.277921822	0.258615417	0.324273151	0.289383339	0.281245928	0.38586218	0.378070476	0.310790579	0.304700817	0.367194003	0.432665587	0.330868177	0.4051154	0.39727051	0.387989608	0.234256371	0.324087001	0.252738398	0.335495332	0.209604804	0.229815366	0.286537904	0.304461482	0.245638109	0.278081379	0.631127989	0.642243798	0.65030143	0.623203321	0.303557325	0.296776149	0.291058688	0.296882521
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	formula	mz	neutral_mass	refmet_name	rt
3-methyl-2-oxovalerate	C6H10O3	0	130.063	3-Methyl-2-oxovaleric acid	0
ketoleucine	C6H10O3	0	130.063	Ketoleucine	0
ketoisovalerate	C5H8O3	0	116.0473	Ketoisovaleric acid	0
METABOLITES_END
#END